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Abstract The aims of this paper are to report hepatitis B virus
reactivation in 12 patients with rheumatic disease undergoing
immunosuppressive therapy and to evaluate whether pre-
emptive antiviral therapy is necessary in patients receiving
disease-modifying anti-rheumatic drugs. From January 2008 to
March 2012, a total of 12 HBV-infected patients with rheumatic
diseases were consecutively enrolled in the long-term follow-up.
Liver function, HBV DNA, and serum aminotransferase level
were tested during the follow-up.We also reviewed the published
reports and summarized the clinical characteristics of HBV
reactivation during immunosuppressive therapy in patients with
rheumatic diseases. The medium duration of follow-up was
41 months (range 16–48). Patients were treated with prednisone,
disease-modifying anti-rheumatic drugs (DMARDs) or tumor
necrosis factor-alpha-blocking agents (TNFBA). HBV reactiva-
tion was only documented in two patients treated with predni-
sone without pre-emptive antiviral therapy. One hundred patients
from literature review were identified as having HBV reactiva-
tion; 20.8 % of the patients receiving prednisone experienced
HBV reactivation compared to only 4.46 and 9.52 % of patients
treated with DMARDs or TNFBA, respectively. This long-term
follow-up of serial cases suggests that pre-emptive antiviral
therapy should be administered in patients receiving prednisone
therapy for rheumatic disease. In contrast, DMARDs and
TNFBA are relatively safe to HBV-infected patients with rheu-
matic diseases. Close monitoring of HBV DNA and ALT levels
is necessary in the management of HBV reactivation.
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Introduction
Hepatitis B virus (HBV) infection is a global health
problem, resulting in more than 350 million people
worldwide [1]. Chronic infection with HBV can lead
to cirrhosis, hepatic decompensation, and hepatocellular
carcinoma.
HBV reactivation in patients undergoing chemotherapy or
immunosuppressive therapy has been a well-recognized com-
plication [2]. However, most of these reports have come from
the fields of oncology and transplantation. The emergence of
immunosuppressive therapy as a key therapeutic option for
patients with rheumatoid disease has been associated with
increasing reports of HBV reactivation.
EASL clinical practice guidelines updated its recommen-
dations for management of chronic hepatitis in 2012, claiming
that HBsAg-positive candidates for chemotherapy and immu-
nosuppressive therapy should be tested for HBV DNA levels
and should receive pre-emptive nucleotide or nucleoside ana-
logue administration during therapy (regardless of HBVDNA
levels) and lasting for 12months after cessation of therapy [3].
However, pre-emptive therapy in patients with rheumatic
diseases treated with disease-modifying anti-rheumatic drugs
(DMARDs) or tumor necrosis factor-alpha-blocking
(TNFBA) is still a matter of controversy.
We conducted this long-term follow-up of serial cases and
literature review to access and summarize the current evidence
of HBV reactivation in HBV-infected patients with rheumatic
diseases who receive different immunosuppressive therapy,
including steroids, DMARDs, and TNFBA. We also evaluat-




From January 2008 to March 2012, HBV-infected patients
who were candidates for immunosuppressive therapy for
newly diagnosed rheumatic diseases were consecutively en-
rolled in the long-term follow-up. Patients were excluded if
they had the evidence of autoimmune hepatitis, prior exposure
to immunosuppressive therapy or coinfection with hepatitis C
or D before the administration. Finally, a total of 12 patients
were consecutively enrolled in the long-term follow-up. Pa-
tients were treated with prednisone, DMARDs, or TNFBA.
HBV markers, HBV DNA, and ALT levels were tested at
baseline and every 2–3 months during the follow-up. This
study protocol was approved by the ethics committee of our
hospital, and informed consent was obtained from enrolled
patients.
Review of the literature
We search the PubMed databases using the MeSH term “hep-
atitis B virus” combined with the terms “DMARDs”, “ste-
roid”, “prednisone”, “methotrexate”, “leflunomide”,
“hydroxychloroquine”, “salicylazosulfapyridine”, “cyclo-
phosphamide”, “azathioprine”, “etanercept”, “infliximab”,
“adalimumab”, “rituximab” and “rheumatoid disease”.
Thirty-seven articles describing 991 patients having HBV
reactivation were retrieved. These patients were identified as
having chronic HBV infection or past HBV infection.
Definitions
Past HBV infection was defined as positive for anti-HBc (anti-
HBc+) and negative for HBsAg (HBsAg−) [4]. Chronic HBV
infection was defined as the persistent positivity of HBsAg in
serum. HBV reactivation was defined as an elevation of both




From January 2008 toMarch 2012, a total of 12 HBV-infected
patients with rheumatic diseases were consecutively enrolled
in the long-term follow-up. Table 1 showed the demographic
characteristic of the 12 patients. Medium age of the 12 patients
was 42.5 years old (range 17–74). Seven of the 12 patients
were male. Only one patient was negative for HBsAg at
baseline. The level of HBV DNAwas not obtained at baseline
in two patients. Patients were treated with prednisone,
DMARDs, and TNFBA. The medium duration of follow-up
was 41 months (range 16–48). Treatment regimens were
summarized in Table 1.
Hepatitis reactivation in different treatment regimens
Prednisone was administered in four of the 12 patients (patients
1, 2, 3 and 4). Patients 3 and 4 were prescribed pre-emptive
antiviral therapy. DMARDs were administered in five patients
(patients 5, 6, 7, 8 and 9). The remaining three patients (patients
10, 11 and 12) were treated with the TNFBA.
HBV reactivation was only documented in two patients
(patients 1 and 2). Patient 1 was treated with prednisone alone,
and patient 2 was treated combination therapy of prednisone
and azathioprine. Neither of them received the pre-emptive
therapy (Fig. 1). In contrast, the other two patients who re-
ceived pre-emptive antiviral therapy before prednisone admin-
istration did not develop the HBV reactivation (Fig. 2). HBV
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reactivation was not observed in patients treated with
DMARDs (Fig. 3) or TNFBA (Fig. 4) during the follow-up.
HBV DNA level increased in one patient after LEF adminis-
tration. After the withdrawal of LEF, the level of HBV DNA
turned to normal. The level of ALT remained normal during the
3-year follow-up in patients who did not develop HBV
reactivation.
Hepatitis reactivation in two cases
Case 1 A 41-year-old man who was diagnosed with dermato-
myositis in January 2008. Tests for hepatitis B virus
markers, HBsAg, anti-HBc and anti-HBe yielded pos-
itive findings. The level of serum HBV DNA was
under detectable limit and liver function was normal.
He was treated with methylpredinisolone therapy
(40 mg/day). One month later, serum level of ALT
increased to 112 U/L (more than two-folds of normal
limit), and serum level of HBV DNA increased to
6.41×103 copies/ml meanwhile. Despite antiviral ther-
apy with lamivudine, the level of ALTand HBV DNA
was still high. Adefovir was added to lamivudine
(10 mg/day) 4 months later. After 9 months of combi-
nation therapy, the level of ALT and HBV DNA
Table 1 The baseline characteristics and treatment regimen of the 12 patients enrolled





1 DM M/41 + − <103 No Pred/48 Pred 50 mg qd, now reduce to 5 mg qd
2 DM F/74 − − Not done No Pred+AZA/16, died
of cerebral infarction
Pred 50–20 mg qd+AZA 50 mg qd * 9 m
3 SLE F/63 + + 2.36×105 ETV Pred/45 Pred 40 mg qd, now reduce to 5 mg qd
4 SCLE F/49 + + 1×107 ETV Pred/30 Pred 50 mg qd, now reduce to 5 mg qd
5 AS M/50 + − <103 No SASP+MTX/34 SASP 0.5 tid * 2 m MTX 10 mg qw
* 24 m
6 AS M/29 + − 1.6×103 No SASP+MTX/44 SASP 1.0 bid+MTX 10 mg qw * 6 m
now SASP 1.0 bid * 26 m
7 AS M/20 + + 2.35×107 No SASP/48 SASP 1.0 bid
8 RA F/67 + + 4.46×104 No MTX/47 MTX 7.5 mg qw
9 AS M/17 + − <103 No SASP+MTX/47 SASP 1.0 bid+MTX 5 mg qw * 3 m
now withdraw
10 AS M/24 + + 2.43×105 No ETN/46 ETN 25 mg qw * 3 m, 25 mg q2w
* 2 m, 12.5 mg qm * 21 m
11 RA F/44 + − <103 No HCQ/LEF+ETN/44 HCQ 0.2 bid+ETN 25 mg biw * 5 m
LEF 10 mg qn+ETN 25 mg qw * 2 m
ETN 25 mg qw * 20 m
12 AS M/20 + + Not done No SASP+ETN/43 SASP 1.0 bid+ETN 25 mg biw * 3 m
Now withdraw
AS ankylosing spondylitis, AZA azathioprine, DM dermatomyositis, ETN entanercept, ETV entecavir, HBeAg hepatitis B e antigen, HBsAg hepatitis B
surface antigen, HBV hepatitis B virus, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, Pred prednisone, RA rheumatoid arthritis,
SASP salazosulfapyridine, SCLE subacute cutaneous lupus erythematosus, SLE systemic lupus erythematosus
a b
Fig. 1 The clinical course of the two patients who developed HBV
reactivation during prednisone therapy without pre-emptive therapy. a
The clinical course of patient 1, a 41-year-old man diagnosed as DM and
treated with predinisolone. b The clinical course of patient 2, a 74-year-
old female diagnosed as DM and treated with predinisolone plus AZA.
ADV adefovir, AZA azathioprine, DM dermatomysitotis, ETV entecavir,
LAM lamivudine
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returned to normal. LEF was added in October 2008.
Serum levels of ALT and HBV DNA remained persis-
tently normal in the following 3 years (Fig. 1a).
Case 2 A 74-year-old woman who was diagnosed with der-
matomyositis in March 2008. Regular laboratory test
revealed normal serum ALT levels, and HBV sero-
logical marker was negative for HBsAg but positive
for anti-HBc and anti-HBe. Serum levels of HBV
DNA were undetectable before treatment with
methylpredinisolone (40 mg/day) and AZA (50–
a b
Fig. 2 The clinical course of the two patients who received steroid therapy with pre-emptive therapy. Neither of them developed HBV reactivation. a




Fig. 3 The clinical course of the five patients who received DMARDs without pre-emptive therapy. None of them developed HBV reactivation. a
Patient 5. b Patient 6. c Patient 7. d Patient 8. e Patient 9
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100 mg/day). Six months later, no flare of ALT was
observed but serological test revealed that she was
positive for HBsAg. Twelve months later, hepatitis
reactivation occurred. Serum levels of ALT in-
creased to 146 U/L, and circulating HBV DNAwas
detectable at levels of 1.7×107 copies/ml. Entecavir
at a daily dose of 0.5 mg was started. After 3 months
of antiviral therapy, serum levels of ALT decreased
to 43 U/L, and serum levels of HBVDNA decreased
to 1.68×103 copies/ml (Fig. 1b). Unfortunately, the
patient died of cerebral infarction during the follow-
up.
Literature review
Thirty-seven articles describing 991 patients with rheumatic
diseases exposed to different immunosuppressive therapy
were retrieved [5–41]. One hundred forty-four patients re-
ceived steroids. Two hundred twenty-four patients received
DMARDs and 620 patients received TNFBA. There were also
three patients treated with anti-CD20. The summary of the
literature review was shown in Table 2.
With regard to HBV infection status, 609 patients had past
infection and 305 patients were considered to have chronic
hepatitis B. Seventy-seven patients were not detected for the
serum HBV markers at baseline.
Patients treated with DMARDS [9, 12–14, 28] Two hundred
twenty-four patients were treated with DMARDS. Among them,
192 patients had past HBV infection and the other 32 patients
were considered to have chronic hepatitis B. A total of four
patients with chronic hepatitis B infection received antiviral
prophylaxis therapy. HBV reactivation was reported in ten cases
[9, 12–14, 28] (4.46%)with amedian follow-up of 13.2months.
MTX was administered in eight of the ten patients with HBV
reactivation [9, 12–14, 28]. HBV reactivation after the initiation
of LEF [13], HCQ [13], SASP [13] therapy were also reported.
Antiviral therapy was started after HBV reactivation. ETV
seemed to be the preferred option. A satisfied response to the
antiviral therapy was observed in most cases. Two patients [13]
did not receive antiviral therapy despite the HBV reactivation.
Serum levels of HBV DNAwere markedly elevated in one case
but remained persistently normal in the other case. Patient with
bad outcome was only reported by Satoshi Ito [28], in which the
patient died of fulminant hepatitis after a 28-month follow-up in
spite of the treatment with interferon-b.
Patients treated with TNFBA [7, 8, 10–12, 14, 15, 17, 19, 20,
22, 23, 25–27, 29–33, 35–38, 40] Six hundred twenty pa-
tients were treated with TNFBA. Among them, 416 patients
had past infection with HBV and 204 patients had chronic
HBV infection. Antiviral prophylaxis therapy was adminis-
tered in 36 patients with chronic viral infection. HBV reacti-
vation was reported in 59 (9.52 %) patients, in whom 13
patients were with past infection while the remaining 46
patients were chronic infection. Treatment with ETA or INF
for rheumatic diseases was reported in most cases. Followed
by the appearance of viral reactivation, the antiviral therapy
was immediately started. Bad outcome was seen in only one
a b
c
Fig. 4 The clinical course of the three patients who underwent TNFBAwithout pre-emptive therapy. None of them developed HBV reactivation. a
Patient 10. b Patient 11. c Patient 12
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case [23], in which the patient suffered liver failure and died
after 26 months of follow-up.
Patients treated with steroids [5, 6, 21, 24, 34, 39] Steroids
were usually co-administered with DMARDs or TNFBA for
treating rheumatic diseases. This may explain why only 6
articles reporting 144 patients were included. However, the
effect of steroids on hepatitis reactivation cannot be denied. A
total of 30 (one with past infection and the others with chronic
infection) of the 144 patients experienced the HBV reactiva-
tion after a median time of 9.8 months. Serum HBV markers
prior to steroid therapy were detailed in 67 patients. Among
them, only one patient was defined as past infection and the
other 66 patients were chronic infection. Four out of the seven
articles were case reports [5, 21, 34, 39] concerning six
patients with rheumatic diseases affected by hepatitis B virus.
Bae [39] reported a fatal case of hepatitis B virus (HBV)
reactivation during long-term, very-low-dose steroid treat-
ment in an inactive HBV carrier. The patients was treated with
prednisone combined with DMARDs (SSZ and HCQ), how-
ever the reactivation of HBV was mainly attributed to the
steroid according to the author's opinion. There are two cases
[21, 34] that reported steroid monotherapy for treating rheu-
matoid disease. None of the patients received prophylaxis
treatment and developed HBV reactivation after 5 and
9 months of the administration, respectively. Another case
[5] showed hepatic failure due to fibrosing cholestatic hepati-
tis in a patient with pre-surface mutant hepatitis B virus and
mixed connective tissue disease treated with prednisolone and
chloroquine. Similar to the patient treated with low dose of
steroid [39], chloroquine was prescribed to supplement the
steroid treatment. Both patients died of liver failure. HBV
reactivation in patient with past HBV infection after ste-
roid therapy [34] was also reported. A brief report of
prospective study on a comparison of a standard-dose
prednisone regimen and mycophenolate mofetil combined
with a lower prednisone dose in Chinese adults with
idiopathic nephrotic syndrome who were carriers of hepa-
titis B surface antigen [24] were included in this study.
The result of study showed that rate of reactivation was
higher in prednisone regimen than in combination therapy
group, confirming that the impact of prednisone on the
viral reactivation. Another retrospective study [6] reported
HBV reactivation following GC therapy for a case series
of pemphigus vulgaris and dermatomyositis. Four out of
the 98 patients finally had a reactivation after a median time of
10.5 months.
Patients treated with anti-CD20 [16, 18, 41] Rituximab is the
representative of anti-CD20, which is also a kind of biological
DMARD. Only one patient [18] underwent the HBV reacti-
vation and was treated with LAM combined with tenofovir. A
good response to the treatment was received.
Discussion
Clinical cases about HBV reactivation in patients with rheu-
matic disease after immunosuppressive therapy have been
increasing, which suggests the possibility of HBV reactivation
in the patients receiving immunosuppressive treatment for rheu-
matic diseases. Recent researches of HBV reactivation leading
to serious complications have been described in patients with
rheumatic disease undergoing treatment with biological agents,
mainly including infliximab and rituximab [19, 42]. Consider-
ing the potential risk of biological agents, pre-emptive antiviral
treatment is recommended in HBsAg-positive patients at the
commencement of TNFBA treatment [8].
We presented the result of three patients who received bio-
logical agents (entanercept) in this study. HBV reactivation oc-
curred in none of them. There are, however, observations from
our literature review suggesting that 59 patients in 620 cases
finally experienced the hepatitis reactivation. The result suggests
the potential of TNFBA to induce viral reactivation. Once the
anti-TNF agents were withdrawn and antiviral therapy was giv-
en, the level of liver enzyme andHBVDNAdecreased to normal
[43] and patients came through in most cases. Hepatitis reactiva-
tion usually occurred 30–60 days after immunosuppressive
therapy. Antiviral prophylaxis treatment is recommended
in HBsAg-positive patients. Since the publication and
selection bias cannot be avoided, a bigger and longer
follow-up study is required to clarify the influence on
hepatitis reactivation after anti-TNF-alpha treatment.
SASP andMTX are the commonly single-use DMARDs in
rheumatic patients. The possibility of DMARDs to induce
HBVreactivation is still a controversial issue in recent studies.
In our serial cases, five patients received SASP therapy, and
none of them developed hepatitis reactivation regardless of
serum levels of HBV DNA prior to SASP therapy. No re-
search approves that SASP induce hepatitis reactivation. We
believe SASP is safe on hepatitis B patients. Four patients
were treated with MTX therapy and no HBV reactivation was
observed during follow-up. In our literature review, most
cases were treated with MTX as a preferred choice. A few
researches reported HBV reactivation during or after MTX
therapy [17, 28, 44]. One of them progressed to fatal hepatic
failure in the end [44]. According to the result of the literature
review, DMARDs seem to be the safest medicine considering
only 4.46 % of the patients experienced HBV reactivation
after the treatment.
The efficacy of prednisone on hepatitis reactivation is
proved again. In this study, HBV reactivation occurred in
patients who did not receive pre-emptive therapy. Results
from some research suggested that the risk of hepatitis
reactivation depends on the dosage of prednisone [24].
However, in our literature review, this assumption was
not proved. Prophylaxis antiviral therapy is necessary in
those hepatitis B-infected patients who will receive
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prednisone therapy. Optimal agent for pre-emptive therapy
is still controversial. The benefits of LAM may be limited
due to resistance and entecavir is recommended as first
choice for pre-emptive therapy. HBV reactivation induced
by prednisone has been investigated thoroughly in cancer
patients receiving chemotherapy treatment and some
consensus has been made. However, in the field of
rheumatism, the subject seemed to be anything but a
hotspot. Thirty of the 144 patients experienced HBV
reactivation in the literature review, which strongly sug-
gested the necessity to prescribe antiviral pre-emptive
therapy.
HBV reactivation also occurs in HBV-infected patients
who were negative for HBsAg but positive for anti-HBc. In
this study, a 74-year-old woman who was negative for HBsAg
before the commencement of prednisone therapy experienced
HBV reactivation 11 months after prednisone administration.
Reactivation of HBV infection has been reported in HBsAg-
negative patients who received chemotherapy [45] for lym-
phoma. Observation of the literature review also confirmed
the possibility of viral reactivation in patients with past HBV
infection treated with immunosuppressive therapy for rheu-
matic diseases. Nineteen of the 609 patients (3.20%)with past
infection experienced reactivation after immunosuppressive
therapy. Taking these lines of evidence together, serum levels
of ALT and HBV DNA should be monitored not only in
patients who were chronically infected, but also in patients
who have past infection (negative for HBsAg and positive for
anti-HBc).
The time of HBV reactivation is still not confirmed, based
on our study. Not surprisingly, reactivation was observed
during the treatment with immunosuppressive therapy. How-
ever, even after the drug withdrawal, the reactivation still
occurred [8]. Therefore, the whole course of the therapy,
instead of the first few months, ought to be monitored closely.
In conclusion, HBV reactivation also occurs in patients
with rheumatic diseases treated with immunosuppressive ther-
apy. Pre-emptive therapy is proved beneficial in cancer pa-
tients with hepatitis B. However, pre-emptive therapy in pa-
tients with rheumatic diseases treated with different immuno-
suppressive therapy is still a matter of controversy. In terms of
our study, the benefits of pre-emptive therapy definitely ex-
ceed the harm of it in patients receiving steroids. Entecavir is
recommended as the optimal agent against HBV reactivation.
On the other hand, DMARDs is shown to be quite safe in
rheumatic patients with HBV infection so that pre-emptive
therapy may not be recommended in these patients. TNFBA is
considered safe in HBsAg-negative patients, while pre-
emptive is required in patients who are positive for HBsAg.
Unnecessary antiviral therapy may induce virus mutation and
further increases the economic burden. Despite the lower risk
of HBV reactivation in patients with rheumatic diseases who
are candidates for DMARDs and TNFNA therapy, such
patients should be followed-up periodically and tested for
ALT and HBV DNA.
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